BILL ANALYSIS

HR7478

BEARISH

Patient Debt Relief Act

HR7478 (Patient Debt Relief Act) has been assessed with a bearish outlook for investors. This legislation directly affects HCA Healthcare ($HCA) and $UHS. The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.

bearish

Market Sentiment

Affected Stocks

Sectors Impacted

Key Takeaways for Investors

HR7478 imposes Medicare compliance costs and collection restrictions on hospitals with zero offsetting benefits for for-profits

HCA and UHS have already declined 9.2% and 6% respectively in the trailing 30 days as the market prices this risk

Bill is early-stage (referred to committee) with low near-term passage probability, but regulatory overhang may persist

How HR7478 Affects the Market

The market is correctly discounting HCA and UHS on this regulatory threat. HCA at $429.70 is near its 52-week low of $330; UHS at $168.24 is near $152.33. Both have further downside if the bill gains committee momentum, but also have a potential catalyst for recovery if the bill dies in committee—a likely scenario given the divided Congress. Investors should monitor committee assignments and hearing schedules for Energy & Commerce and Ways & Means.

Bill Details

Metric	Value
Bill Number	HR7478
Market Sentiment	bearish
Event Date	February 10, 2026
Affected Sectors	Healthcare
Affected Stocks	HCA Healthcare ($HCA), $UHS
Source	View on Congress.gov →

Summary

The Patient Debt Relief Act (HR7478) imposes new Medicare compliance costs on hospital operators without providing offsetting reimbursement benefits. For-profit chains HCA and UHS are directly exposed. The bill is early-stage, but both stocks have already declined significantly over the trailing 30 days as the market prices in the regulatory overhang.

Full AI Market Analysis

1) WHAT HAPPENED: HR7478 was introduced February 10, 2026 by Rep. Vasquez (D-NM) with 18 cosponsors, all Democrats. The bill was referred to both the Energy and Commerce Committee and Ways and Means Committee. It has had no subsequent actions—it is early-stage with a long legislative path ahead. 2) MONEY TRAIL: The bill does not authorize or appropriate any new funding. It imposes new regulatory conditions on hospitals that participate in Medicare, with civil monetary penalties up to $1 million per noncompliance instance. The grant program for medical debt relief is authorized but not funded—a separate appropriations bill would be needed. 3) STRUCTURAL WINNERS AND LOSERS: For-profit hospital chains HCA and UHS are the clearest losers. They operate large portfolios of Medicare-dependent hospitals and lack the charitable mission offsets that not-for-profit and public hospitals can claim. Not-for-profit systems like HCA's competitors may face lower net compliance costs due to existing charity care infrastructure. 4) MARKET DATA: Real data confirms the bearish read. HCA fell from $488 on April 17 to $429.70 on April 30—a 9.2% decline. UHS fell from $182.41 to $168.24—a 6% decline. Both are now near their 52-week lows. The selloff accelerated after April 24, suggesting growing market recognition of the bill's potential impact despite its early stage. 5) TIMELINE: The bill faces hearings, markups, floor votes in both chambers, and potential signing. Given unified Democratic sponsorship and a Republican-controlled House, near-term passage is highly unlikely. However, regulatory risk will persist through the 119th Congress, creating continued overhang.